CO6260132A2 - Derivados de oxadiazol como inhibidores de dgat - Google Patents

Derivados de oxadiazol como inhibidores de dgat

Info

Publication number
CO6260132A2
CO6260132A2 CO10016765A CO10016765A CO6260132A2 CO 6260132 A2 CO6260132 A2 CO 6260132A2 CO 10016765 A CO10016765 A CO 10016765A CO 10016765 A CO10016765 A CO 10016765A CO 6260132 A2 CO6260132 A2 CO 6260132A2
Authority
CO
Colombia
Prior art keywords
alkyl
heteroarylalkyl
heterocycloalkyl
cycloalkyl
arylalkyl
Prior art date
Application number
CO10016765A
Other languages
English (en)
Inventor
James Arnold
Todd Brugel
Phil Edwards
Andrew Griffin
Thierry Groblewski
Denis Labrecque
Scott Throner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6260132A2 publication Critical patent/CO6260132A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Abstract

1.- Un compuesto de fórmula I o diaestereoisómeros o enantiómeros de ellos, o sales farmacéuticamente aceptables de fórmula I o diaestereoisómeros o enantiómeros de ellas, o mezclas de los mismos:en donde A es arilo, heteroarilo, cicloalquilo o heterocicloalquilo; m es 1 ó 2; n es 1, 2, 3, 4 ó 5; cada R1 es independientemente H, arilo, heteroarilo, arilalquilo, heteroarilalquilo, cicloalquilo, heterocicloalquilalquilo, alquiloC1-C6, alqueniloC2-C6, cicloalqueniloC3-C6, alquiniloC2-C6, alcoxialquilo, hidroxialquilo, aminoalquilo, aminocarbonilalquilo, heterociclo, arilalquenilo, cicloalquenilalquilo, heterocicloalquilo, ciano, alquilsulfinilo, haloalquilo, NR4R5, -NR6C(=O)R3, -NHS(O)2R3, -C(=O)NR4R5, alcoxi, halógeno, alquilcarbonilo o hidroxi (-OH); R2 es arilo, heteroarilo, cicloalquilo, alquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, arilalquenilo o cicloalquilalquilo; en donde R2 está opcionalmente sustituido con por lo menos un cicloalquilo; R3 es H, alquiloC1-C6, alcoxiC1-C6, -NHaIquiloC1-C6 o -N(alquiloC1-C6)2 o R3 y el N del grupo -NR6C(=O)R3 forman juntos un anillo heterocíclico de 4, 5 ó 6 miembros que tiene por lo menos un heteroátomo seleccionado entre O y N; R4 y R5 se seleccionan cada uno independientemente entre H y alquiloC1-C6 o R4, R5 y el N al que están unidos, forman juntos un anillo heterocíclico de 4,5 ó 6 miembros que tiene por lo menos un heteroátomo seleccionado entre N; y R6 es H o está ausente; siempre que cuando i) R2 es heteroarilalquilo, el heteroarilalquilo no es en donde X es un O o N y R' y R" son cada uno independientemente H o alquiloC1-20; ii) N y R3 están unidos, R6 está ausente; y iii) A es fenilo, R2 no es fenilo no sustituido.
CO10016765A 2007-08-22 2010-02-15 Derivados de oxadiazol como inhibidores de dgat CO6260132A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95718107P 2007-08-22 2007-08-22

Publications (1)

Publication Number Publication Date
CO6260132A2 true CO6260132A2 (es) 2011-03-22

Family

ID=40279129

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10016765A CO6260132A2 (es) 2007-08-22 2010-02-15 Derivados de oxadiazol como inhibidores de dgat

Country Status (36)

Country Link
US (3) US8063215B2 (es)
EP (3) EP2195293B1 (es)
JP (1) JP4691669B2 (es)
KR (2) KR101588466B1 (es)
CN (1) CN101835750B (es)
AR (1) AR067996A1 (es)
AU (1) AU2008290329B2 (es)
BR (1) BRPI0815591B8 (es)
CA (1) CA2697256C (es)
CO (1) CO6260132A2 (es)
CR (1) CR11290A (es)
CU (1) CU23870B1 (es)
CY (1) CY1114805T1 (es)
DK (1) DK2195293T3 (es)
DO (1) DOP2010000062A (es)
EA (2) EA201200429A1 (es)
EC (1) ECSP10010018A (es)
ES (1) ES2442926T3 (es)
GT (1) GT201000045A (es)
HK (2) HK1144687A1 (es)
HN (1) HN2010000352A (es)
HR (1) HRP20140047T1 (es)
MX (1) MX2010001679A (es)
NI (1) NI201000031A (es)
NZ (1) NZ584100A (es)
PE (1) PE20091077A1 (es)
PH (1) PH12013502616A1 (es)
PL (1) PL2195293T3 (es)
PT (1) PT2195293E (es)
RS (1) RS53144B (es)
SA (1) SA08290520B1 (es)
SI (1) SI2195293T1 (es)
TW (2) TW201446748A (es)
UA (1) UA101809C2 (es)
WO (1) WO2009024823A2 (es)
ZA (1) ZA201000885B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN101472887A (zh) 2006-06-23 2009-07-01 艾博特公司 作为组胺h3受体调节物的环丙胺衍生物
SI2195293T1 (sl) 2007-08-22 2014-02-28 Astrazeneca Ab Derivati ciklopropil amida
US20090170869A1 (en) 2007-09-06 2009-07-02 Desmond John Best Piperazine derivative having affinity for the histamine h3 receptor
US8912176B2 (en) 2009-02-02 2014-12-16 Evotec Ag Azetidines as histamine H3 receptor antagonists
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011102793A1 (en) * 2010-02-18 2011-08-25 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
SG183274A1 (en) * 2010-02-18 2012-09-27 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US10980806B2 (en) * 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
WO2023199091A1 (en) * 2022-04-12 2023-10-19 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (es) * 1963-04-04 1900-01-01
NL128365C (es) 1963-11-05
US3449427A (en) * 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) * 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
CS244821B2 (en) 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
DE3418167A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de) 1986-05-28 1987-12-03 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
EP0435320B1 (en) * 1989-12-29 1994-10-05 Banyu Pharmaceutical Co., Ltd. 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives
EP0603240B1 (en) 1991-08-22 1998-12-02 Monsanto Company Safening herbicidal pyrazolylsulfonylureas
DE4131139A1 (de) 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
US5721359A (en) 1993-03-12 1998-02-24 Pharmacia & Upjohn Company Crystalline ceftiofur free acid
BR9509760A (pt) 1994-11-23 1998-06-30 Neurogen Corp Composto
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
EP0968200A1 (en) 1997-02-24 2000-01-05 ZymoGenetics, Inc. Calcitonin mimetics
US6160134A (en) 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
UA59433C2 (uk) 1998-01-27 2003-09-15 Авентіс Фармасьютікалс Продактс Інк. ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
EP1090919A4 (en) 1998-06-26 2002-05-22 Chugai Pharmaceutical Co Ltd L-ALPHA-AMINOADIPIC ACID DERIVATIVE IN FINE POWDER, ORAL SOLID PREPARATIONS CONTAINING SAID DERIVATIVE AND BULK POWDER PROCESSING PROCESS
US6284761B1 (en) * 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
NZ512772A (en) * 1999-01-08 2003-11-28 Neurogen Corp 1-Phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines useful as dopamine receptor ligands
AU5426500A (en) 1999-06-16 2001-01-02 Takeda Chemical Industries Ltd. Benzazepine derivatives, process for the preparation of the same and uses thereof
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
JP2004502672A (ja) 2000-06-29 2004-01-29 アボット・ラボラトリーズ 細胞接着阻害抗炎症剤および免疫抑制剤としてのアリールフェニルシクロプロピルスルフィド誘導体およびその使用
EP1301484A2 (en) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
JPWO2002051781A1 (ja) 2000-12-25 2004-04-22 味の素株式会社 光学活性ハロヒドリン化合物の製造方法
CZ20032258A3 (cs) * 2001-02-23 2004-01-14 Merck & Co., Inc. N-substituované nearylové heterocyklické sloučeniny
EP1421071B1 (en) 2001-07-02 2009-11-18 High Point Pharmaceuticals, LLC Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators
WO2003014110A1 (fr) 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Derive de benzazepine, son procede de preparation et d'utilisation
WO2003026572A2 (en) 2001-09-26 2003-04-03 Merck & Co., Inc. Crystalline forms of ertapenem sodium
US20050143372A1 (en) * 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
EP1487826A4 (en) 2002-03-22 2005-06-29 Lg Life Sciences Ltd NOVEL (2S) -N-5- (AMINO (IMINO) METHYL) -2-THIENYLMETHYL-1- (2R) -2 - ((CARBOXYMETHYL) AMINO) -3,3-DIPHENYLPROPANOYL-2-PYRROLIDINECARBOXAMIDE CRYSTALLINE FORMS. nH2O
WO2003103666A2 (en) 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
US20040077618A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040209858A1 (en) * 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
US7569579B2 (en) 2002-12-13 2009-08-04 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
PT1615909E (pt) 2003-04-23 2008-10-30 Glaxo Group Ltd Derivados de piperazina e a sua utilização para o tratamento de doenças neurológicas e psiquiátricas
DE602004029242D1 (en) 2003-05-01 2010-11-04 Bristol Myers Squibb Co Pyrazolamidverbindungen
AR045595A1 (es) * 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
JP2007516982A (ja) 2003-12-15 2007-06-28 日本たばこ産業株式会社 シクロプロパン化合物及びその医薬用途
BRPI0418939A (pt) 2004-07-06 2008-04-08 Xenon Pharmaceuticals Inc derivados de nicotinamida e sua utilização como agentes terapêuticos
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
SI1805164T1 (sl) 2004-09-29 2011-05-31 Mitsubishi Tanabe Pharma Corp 6-(piridinil)-4-pirimidonski derivati kot inhibitorji tau protein kinaze 1
SI1802307T1 (sl) 2004-10-15 2008-08-31 Glaxo Group Ltd Derivati pirolidina kot ligandi histaminskih receptorjev
WO2006071730A1 (en) 2004-12-27 2006-07-06 Astrazeneca Ab Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders
CA2595882A1 (en) 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
EP1848695B1 (en) 2005-02-15 2011-07-27 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
JP2008534488A (ja) 2005-03-25 2008-08-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 血小板凝集阻害剤としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物
WO2006103555A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
EP1869051A1 (en) 2005-03-28 2007-12-26 Pharmacia & Upjohn Company LLC 4-piperazinylthieno ý2,3-d¨pyrimidine compounds as platelet aggregation inhibitors
CA2603041A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
JP2009501235A (ja) 2005-07-15 2009-01-15 シェーリング コーポレイション 癌処置において有用なキナゾリン誘導体
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
US7851474B2 (en) 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
CA2622760C (en) 2005-09-16 2012-12-04 Janssen Pharmaceutica N.V. Cyclopropyl amines as modulators of the histamine h3 receptor
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP5185822B2 (ja) 2005-10-31 2013-04-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ シクロプロピル−アミド誘導体の製造方法
CA2633653A1 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007076140A2 (en) 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
CN101374825A (zh) * 2006-01-13 2009-02-25 霍夫曼-拉罗奇有限公司 环己基哌嗪基甲酮衍生物及它们作为组胺h3受体调节剂的应用
CN101384581B (zh) 2006-02-17 2013-09-18 弗·哈夫曼-拉罗切有限公司 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物
EP2004568A4 (en) 2006-03-01 2010-12-01 Cementech Pty Ltd MATRIX FOR WALL ELEMENTS AND MANUFACTURING METHOD THEREFOR
JP2009132621A (ja) 2006-03-13 2009-06-18 Ajinomoto Co Inc シクロプロピルアミド化合物の製造方法
MX2008012064A (es) 2006-03-23 2008-12-17 Amgen Inc Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
EP2039689A4 (en) 2006-05-26 2011-12-28 Kaneka Corp PROCESS FOR PREPARING OPTICALLY ACTIVE 3-AMINO-2-HYDROXYPROPIONIC ACID CYCLOPROPYLAMID DERIVATIVES AND SALTS THEREOF
CN101472887A (zh) 2006-06-23 2009-07-01 艾博特公司 作为组胺h3受体调节物的环丙胺衍生物
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
WO2008003702A2 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine h4 receptor
EP2056828A4 (en) 2006-08-21 2010-06-23 Merck Sharp & Dohme SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS
TW200828371A (en) 2006-09-21 2008-07-01 Matsushita Electric Ind Co Ltd Chip-type filter
DE102006056526A1 (de) 2006-11-30 2008-06-05 Archimica Gmbh Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung
WO2008079902A1 (en) * 2006-12-21 2008-07-03 Neology, Inc. Systems and methods for a rfid enabled metal license plate
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008147864A2 (en) 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
JP2010528007A (ja) 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
JP2010529157A (ja) 2007-06-11 2010-08-26 エフ．ホフマン−ラ ロシュ アーゲー シクロヘキシル誘導体
SI2195293T1 (sl) 2007-08-22 2014-02-28 Astrazeneca Ab Derivati ciklopropil amida
JP5362729B2 (ja) 2007-10-04 2013-12-11 エフ．ホフマン−ラ ロシュ アーゲー シクロプロピルアリールアミド誘導体及びその使用
CL2009000004A1 (es) 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
DE102008049371A1 (de) 2008-03-06 2009-09-10 Mühlbauer Ag Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür
CN102015636B (zh) 2008-05-08 2014-08-13 埃沃特克股份有限公司 作为组胺h3受体拮抗剂的氮杂环丁烷类和环丁烷类化合物
CN105152919A (zh) 2008-07-28 2015-12-16 赛丹思科大学 用于治疗代谢疾病的化合物
CN101462980B (zh) 2009-01-05 2013-01-09 扬州天辰精细化工有限公司 2，6—二氟苯甲酰胺的工业化生产方法
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
WO2011102793A1 (en) 2010-02-18 2011-08-25 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
SG183274A1 (en) 2010-02-18 2012-09-27 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith

Also Published As

Publication number Publication date
CA2697256C (en) 2013-10-15
US20090076020A1 (en) 2009-03-19
NI201000031A (es) 2012-11-07
EA016687B1 (ru) 2012-06-29
NZ584100A (en) 2011-07-29
KR20100080768A (ko) 2010-07-12
KR20150076264A (ko) 2015-07-06
PL2195293T3 (pl) 2014-03-31
CN101835750A (zh) 2010-09-15
AU2008290329A1 (en) 2009-02-26
JP2010536840A (ja) 2010-12-02
SA08290520B1 (ar) 2012-02-22
BRPI0815591B1 (pt) 2020-09-15
ES2442926T3 (es) 2014-02-14
ECSP10010018A (es) 2010-04-30
AR067996A1 (es) 2009-10-28
TW201446748A (zh) 2014-12-16
TWI432422B (zh) 2014-04-01
EA201200429A1 (ru) 2012-08-30
EA201000204A1 (ru) 2010-08-30
SI2195293T1 (sl) 2014-02-28
GT201000045A (es) 2015-01-16
CR11290A (es) 2010-05-28
MX2010001679A (es) 2010-03-11
WO2009024823A3 (en) 2009-04-16
UA101809C2 (uk) 2013-05-13
PT2195293E (pt) 2014-01-21
EA016687B8 (ru) 2012-07-30
CN101835750B (zh) 2013-07-17
US20120065193A1 (en) 2012-03-15
BRPI0815591A2 (pt) 2015-03-03
AU2008290329B2 (en) 2011-12-22
CU20100035A7 (es) 2011-09-21
HN2010000352A (es) 2012-11-12
EP2253615B1 (en) 2014-07-09
EP2805937A1 (en) 2014-11-26
ZA201000885B (en) 2010-11-24
HK1204606A1 (en) 2015-11-27
CU23870B1 (es) 2013-03-27
TW200914436A (en) 2009-04-01
WO2009024823A2 (en) 2009-02-26
US20150216861A1 (en) 2015-08-06
WO2009024823A8 (en) 2010-03-18
DOP2010000062A (es) 2010-05-15
US8063215B2 (en) 2011-11-22
BRPI0815591B8 (pt) 2021-05-25
DK2195293T3 (da) 2014-02-03
EP2195293B1 (en) 2013-10-16
PH12013502616A1 (en) 2014-10-08
JP4691669B2 (ja) 2011-06-01
HK1144687A1 (en) 2011-03-04
CA2697256A1 (en) 2009-02-26
CY1114805T1 (el) 2016-12-14
US9029381B2 (en) 2015-05-12
KR101588466B1 (ko) 2016-01-25
EP2253615A1 (en) 2010-11-24
EP2195293A2 (en) 2010-06-16
HRP20140047T1 (en) 2014-02-14
PE20091077A1 (es) 2009-08-27
RS53144B (en) 2014-06-30

Similar Documents

Publication Publication Date Title
CO6260132A2 (es) Derivados de oxadiazol como inhibidores de dgat
ES2515095T3 (es) Derivados de adamantil acetamida como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR055144A1 (es) Inhibidor de secrecion acida
AR062125A1 (es) Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
PE20130155A1 (es) Derivados de ariletinilo
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
CO6180439A2 (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos
AR079334A1 (es) Derivados de oxazin amino
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
CO6220907A2 (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
ATE556058T1 (de) 1-(2h)-isochinolonderivat
AR043860A1 (es) Compuesto de anillo heteroaromatico de 5 miembros y su uso farmaceutico
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
AR057626A1 (es) Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor
CO6220851A2 (es) Compuestos de ciclohexandiona sustituidos en la posicion 5
ECSP067013A (es) 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4
AR060807A1 (es) Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
CY1122201T1 (el) Παραγωγα βενζοδιοξολιου ως αναστολεις φωσφοδιεστερασης
ECSP088479A (es) Derivados de oxadiazol
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido

Legal Events

Date Code Title Description
FG Application granted